Medlive Technology Co., Ltd. provided consolidated earnings guidance for the year ended 31 December 2022. For the period, the company expects to record an increase in revenue around 10%; and record a significant increase in profit attributable to owners of the parent to not less than RMB 100 million as compared to the profit attributable to owners of the parent of approximately RMB 40.6 million for the year ended 31 December 2021. The increase in revenue for FY2022 was mainly attributable to increase in revenue from the Group's precision marketing and corporate solutions.

Benefitting from the volume-based procurement policy, digital healthcare marketing services became an inevitable development trend and the demand of such services from pharmaceutical and medical device companies has increased. In 2022, the number of users of the Group's Medlive platform and user engagement continued to increase due to the professional medical knowledge content and the enriched medical tools offered by the Group. This further highlighted the business advantage of the Group's precision marketing and corporate solutions.

Furthermore, although the COVID-19 pandemic has affected the normal office practice of the Group and its customers causing delay in the execution of many projects, the Group was able to satisfy the pressing need of pharmaceutical and medical device companies for highly efficient and cost-effective digital marketing solutions. As such, the number of healthcare customers of, and the number of products marketed under, the precision marketing and corporate solutions increased steadily in 2022. The increase in profit attributable to owners of the parent for FY2022 was primarily due to the increase in revenue as aforementioned, coupled with the significant increase in interest income in FY2022 as a result of the increase in market interest rates for bank deposits as compared with FY2021.